Effects of SLCO1B1 polymorphisms on the pharmacokinetics and pharmacodynamics of repaglinide in healthy Chinese volunteers
Purpose Repaglinide is commonly used in the treatment of patients with type 2 diabetes mellitus to reduce postprandial hyperglycemia. The objective of this research was to study the effects of SLCO1B1 polymorphisms on the pharmacokinetics and pharmacodynamics of repaglinide in healthy Chinese volunt...
Gespeichert in:
| Veröffentlicht in: | European journal of clinical pharmacology 2011-07, Vol.67 (7), p.701-707 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 707 |
|---|---|
| container_issue | 7 |
| container_start_page | 701 |
| container_title | European journal of clinical pharmacology |
| container_volume | 67 |
| creator | He, Jiake Qiu, Zhixia Li, Ning Yu, Yang Lu, Yang Han, Deen Li, Tingting Zhao, Di Sun, Wei Fang, Fang Zheng, Jianheng Fan, Hongwei Chen, Xijing |
| description | Purpose
Repaglinide is commonly used in the treatment of patients with type 2 diabetes mellitus to reduce postprandial hyperglycemia. The objective of this research was to study the effects of
SLCO1B1
polymorphisms on the pharmacokinetics and pharmacodynamics of repaglinide in healthy Chinese volunteers.
Methods
A total of 22 healthy young male participants were recruited from a pool of pharmacogenetically characterized participants genotyped for
SLCO1B1
,
CYP3A4
, and
CYP2C8
SNPs by polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP). Volunteers with
CYP2C8*3
and
CYP3A4*4
alleles were excluded from the clinical study. Then selected volunteers took part in the clinical pharmacokinetic study, receiving 2 mg repaglinide.
Results
Healthy participants with
SLCO1B1*1A/*1B
or
*1A/*1A
genotype and
SLCO1B1 *15/*1A
or
*5/*1A
genotype had significantly higher AUC
0-∞
than participants with
SLCO1B1*1B/*1B
genotype, with the former showing an increase over the latter of 39.81 and 42.09%, respectively (
P
= 0.028, 0.032). The clearance in the former two genotype groups was significantly attenuated (by 27.39 and 28.55%, respectively) compared with individuals with
SLCO1B1*1B/*1B
genotype (
P
= 0.015, 0.019). No significant differences in blood glucose-lowering effect were observed among three genotype groups.
Conclusions
SLCO1B1*1B/*1B
genotype is associated with reduced pharmacokinetic exposure after a single dose oral administration of 2 mg repaglinide, including decreased AUC
0-∞
and increased clearance of repaglinide. Moreover, this polymorphism of
SLCO1B1
has significant influence on the pharmacokinetics of repaglinide, but no effects on its pharmacodynamics. |
| doi_str_mv | 10.1007/s00228-011-0994-7 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_journals_871554183</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2373836351</sourcerecordid><originalsourceid>FETCH-LOGICAL-c466t-baae5b89e1c16306807c8b2bbbf3a79632c6d34d0a0c9694b5c20d45e422d38c3</originalsourceid><addsrcrecordid>eNp1kMFu1DAQhi0EotvCA3BBFhLHwIztxPERVoUirdQDcLYcZ9KkJE6ws5WWp8erXdoTJ0sz3_-P9TH2BuEDAuiPCUCIugDEAoxRhX7GNqikKBAUPmcbAIlFZTRcsMuU7gGwNCBfsguBUmgDZsP-XHcd-TXxuePfd9tb_Ix8mcfDNMelH9KUF4GvPfGld3Fyfv41BFoHn7gL7eOwPQQ3HYe5JdLi7sYhDC3xIfCe3Lj2B77tczARf5jHfViJYnrFXnRuTPT6_F6xn1-uf2xvit3t12_bT7vCq6pai8Y5KpvaEHqsJFQ1aF83ommaTjptKil81UrVggNvKqOa0gtoVUlKiFbWXl6xd6feJc6_95RWez_vY8gnba2xLBXWMkN4gnycU4rU2SUOk4sHi2CPsu1Jts2y7VG21Tnz9ly8byZqHxP_7Gbg_Rlwybuxiy74IT1xSmiF8siJE5fyKtxRfPrh_6__BQtrmDE</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>871554183</pqid></control><display><type>article</type><title>Effects of SLCO1B1 polymorphisms on the pharmacokinetics and pharmacodynamics of repaglinide in healthy Chinese volunteers</title><source>MEDLINE</source><source>Springer Nature - Complete Springer Journals</source><creator>He, Jiake ; Qiu, Zhixia ; Li, Ning ; Yu, Yang ; Lu, Yang ; Han, Deen ; Li, Tingting ; Zhao, Di ; Sun, Wei ; Fang, Fang ; Zheng, Jianheng ; Fan, Hongwei ; Chen, Xijing</creator><creatorcontrib>He, Jiake ; Qiu, Zhixia ; Li, Ning ; Yu, Yang ; Lu, Yang ; Han, Deen ; Li, Tingting ; Zhao, Di ; Sun, Wei ; Fang, Fang ; Zheng, Jianheng ; Fan, Hongwei ; Chen, Xijing</creatorcontrib><description>Purpose
Repaglinide is commonly used in the treatment of patients with type 2 diabetes mellitus to reduce postprandial hyperglycemia. The objective of this research was to study the effects of
SLCO1B1
polymorphisms on the pharmacokinetics and pharmacodynamics of repaglinide in healthy Chinese volunteers.
Methods
A total of 22 healthy young male participants were recruited from a pool of pharmacogenetically characterized participants genotyped for
SLCO1B1
,
CYP3A4
, and
CYP2C8
SNPs by polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP). Volunteers with
CYP2C8*3
and
CYP3A4*4
alleles were excluded from the clinical study. Then selected volunteers took part in the clinical pharmacokinetic study, receiving 2 mg repaglinide.
Results
Healthy participants with
SLCO1B1*1A/*1B
or
*1A/*1A
genotype and
SLCO1B1 *15/*1A
or
*5/*1A
genotype had significantly higher AUC
0-∞
than participants with
SLCO1B1*1B/*1B
genotype, with the former showing an increase over the latter of 39.81 and 42.09%, respectively (
P
= 0.028, 0.032). The clearance in the former two genotype groups was significantly attenuated (by 27.39 and 28.55%, respectively) compared with individuals with
SLCO1B1*1B/*1B
genotype (
P
= 0.015, 0.019). No significant differences in blood glucose-lowering effect were observed among three genotype groups.
Conclusions
SLCO1B1*1B/*1B
genotype is associated with reduced pharmacokinetic exposure after a single dose oral administration of 2 mg repaglinide, including decreased AUC
0-∞
and increased clearance of repaglinide. Moreover, this polymorphism of
SLCO1B1
has significant influence on the pharmacokinetics of repaglinide, but no effects on its pharmacodynamics.</description><identifier>ISSN: 0031-6970</identifier><identifier>EISSN: 1432-1041</identifier><identifier>DOI: 10.1007/s00228-011-0994-7</identifier><identifier>PMID: 21327909</identifier><language>eng</language><publisher>Berlin/Heidelberg: Springer-Verlag</publisher><subject>Adult ; Area Under Curve ; Aryl Hydrocarbon Hydroxylases - genetics ; Asian Continental Ancestry Group - genetics ; Asian people ; Biological and medical sciences ; Biomedical and Life Sciences ; Biomedicine ; Carbamates - administration & dosage ; Carbamates - pharmacokinetics ; Cytochrome P-450 CYP2C8 ; Cytochrome P-450 CYP3A - genetics ; Genotype ; Genotype & phenotype ; Humans ; Hypoglycemic Agents - administration & dosage ; Hypoglycemic Agents - pharmacokinetics ; Liver-Specific Organic Anion Transporter 1 ; Male ; Medical sciences ; Organic Anion Transporters - genetics ; Pharmacogenetics ; Pharmacology ; Pharmacology. Drug treatments ; Pharmacology/Toxicology ; Piperidines - administration & dosage ; Piperidines - pharmacokinetics ; Polymerase Chain Reaction ; Polymorphism ; Polymorphism, Restriction Fragment Length ; Polymorphism, Single Nucleotide ; Prescription drugs ; Prospective Studies ; Young Adult</subject><ispartof>European journal of clinical pharmacology, 2011-07, Vol.67 (7), p.701-707</ispartof><rights>Springer-Verlag 2011</rights><rights>2015 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c466t-baae5b89e1c16306807c8b2bbbf3a79632c6d34d0a0c9694b5c20d45e422d38c3</citedby><cites>FETCH-LOGICAL-c466t-baae5b89e1c16306807c8b2bbbf3a79632c6d34d0a0c9694b5c20d45e422d38c3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s00228-011-0994-7$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s00228-011-0994-7$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,776,780,27901,27902,41464,42533,51294</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=24274139$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/21327909$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>He, Jiake</creatorcontrib><creatorcontrib>Qiu, Zhixia</creatorcontrib><creatorcontrib>Li, Ning</creatorcontrib><creatorcontrib>Yu, Yang</creatorcontrib><creatorcontrib>Lu, Yang</creatorcontrib><creatorcontrib>Han, Deen</creatorcontrib><creatorcontrib>Li, Tingting</creatorcontrib><creatorcontrib>Zhao, Di</creatorcontrib><creatorcontrib>Sun, Wei</creatorcontrib><creatorcontrib>Fang, Fang</creatorcontrib><creatorcontrib>Zheng, Jianheng</creatorcontrib><creatorcontrib>Fan, Hongwei</creatorcontrib><creatorcontrib>Chen, Xijing</creatorcontrib><title>Effects of SLCO1B1 polymorphisms on the pharmacokinetics and pharmacodynamics of repaglinide in healthy Chinese volunteers</title><title>European journal of clinical pharmacology</title><addtitle>Eur J Clin Pharmacol</addtitle><addtitle>Eur J Clin Pharmacol</addtitle><description>Purpose
Repaglinide is commonly used in the treatment of patients with type 2 diabetes mellitus to reduce postprandial hyperglycemia. The objective of this research was to study the effects of
SLCO1B1
polymorphisms on the pharmacokinetics and pharmacodynamics of repaglinide in healthy Chinese volunteers.
Methods
A total of 22 healthy young male participants were recruited from a pool of pharmacogenetically characterized participants genotyped for
SLCO1B1
,
CYP3A4
, and
CYP2C8
SNPs by polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP). Volunteers with
CYP2C8*3
and
CYP3A4*4
alleles were excluded from the clinical study. Then selected volunteers took part in the clinical pharmacokinetic study, receiving 2 mg repaglinide.
Results
Healthy participants with
SLCO1B1*1A/*1B
or
*1A/*1A
genotype and
SLCO1B1 *15/*1A
or
*5/*1A
genotype had significantly higher AUC
0-∞
than participants with
SLCO1B1*1B/*1B
genotype, with the former showing an increase over the latter of 39.81 and 42.09%, respectively (
P
= 0.028, 0.032). The clearance in the former two genotype groups was significantly attenuated (by 27.39 and 28.55%, respectively) compared with individuals with
SLCO1B1*1B/*1B
genotype (
P
= 0.015, 0.019). No significant differences in blood glucose-lowering effect were observed among three genotype groups.
Conclusions
SLCO1B1*1B/*1B
genotype is associated with reduced pharmacokinetic exposure after a single dose oral administration of 2 mg repaglinide, including decreased AUC
0-∞
and increased clearance of repaglinide. Moreover, this polymorphism of
SLCO1B1
has significant influence on the pharmacokinetics of repaglinide, but no effects on its pharmacodynamics.</description><subject>Adult</subject><subject>Area Under Curve</subject><subject>Aryl Hydrocarbon Hydroxylases - genetics</subject><subject>Asian Continental Ancestry Group - genetics</subject><subject>Asian people</subject><subject>Biological and medical sciences</subject><subject>Biomedical and Life Sciences</subject><subject>Biomedicine</subject><subject>Carbamates - administration & dosage</subject><subject>Carbamates - pharmacokinetics</subject><subject>Cytochrome P-450 CYP2C8</subject><subject>Cytochrome P-450 CYP3A - genetics</subject><subject>Genotype</subject><subject>Genotype & phenotype</subject><subject>Humans</subject><subject>Hypoglycemic Agents - administration & dosage</subject><subject>Hypoglycemic Agents - pharmacokinetics</subject><subject>Liver-Specific Organic Anion Transporter 1</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Organic Anion Transporters - genetics</subject><subject>Pharmacogenetics</subject><subject>Pharmacology</subject><subject>Pharmacology. Drug treatments</subject><subject>Pharmacology/Toxicology</subject><subject>Piperidines - administration & dosage</subject><subject>Piperidines - pharmacokinetics</subject><subject>Polymerase Chain Reaction</subject><subject>Polymorphism</subject><subject>Polymorphism, Restriction Fragment Length</subject><subject>Polymorphism, Single Nucleotide</subject><subject>Prescription drugs</subject><subject>Prospective Studies</subject><subject>Young Adult</subject><issn>0031-6970</issn><issn>1432-1041</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2011</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>BENPR</sourceid><recordid>eNp1kMFu1DAQhi0EotvCA3BBFhLHwIztxPERVoUirdQDcLYcZ9KkJE6ws5WWp8erXdoTJ0sz3_-P9TH2BuEDAuiPCUCIugDEAoxRhX7GNqikKBAUPmcbAIlFZTRcsMuU7gGwNCBfsguBUmgDZsP-XHcd-TXxuePfd9tb_Ix8mcfDNMelH9KUF4GvPfGld3Fyfv41BFoHn7gL7eOwPQQ3HYe5JdLi7sYhDC3xIfCe3Lj2B77tczARf5jHfViJYnrFXnRuTPT6_F6xn1-uf2xvit3t12_bT7vCq6pai8Y5KpvaEHqsJFQ1aF83ommaTjptKil81UrVggNvKqOa0gtoVUlKiFbWXl6xd6feJc6_95RWez_vY8gnba2xLBXWMkN4gnycU4rU2SUOk4sHi2CPsu1Jts2y7VG21Tnz9ly8byZqHxP_7Gbg_Rlwybuxiy74IT1xSmiF8siJE5fyKtxRfPrh_6__BQtrmDE</recordid><startdate>20110701</startdate><enddate>20110701</enddate><creator>He, Jiake</creator><creator>Qiu, Zhixia</creator><creator>Li, Ning</creator><creator>Yu, Yang</creator><creator>Lu, Yang</creator><creator>Han, Deen</creator><creator>Li, Tingting</creator><creator>Zhao, Di</creator><creator>Sun, Wei</creator><creator>Fang, Fang</creator><creator>Zheng, Jianheng</creator><creator>Fan, Hongwei</creator><creator>Chen, Xijing</creator><general>Springer-Verlag</general><general>Springer</general><general>Springer Nature B.V</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7RV</scope><scope>7TK</scope><scope>7U9</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>H94</scope><scope>K9.</scope><scope>KB0</scope><scope>M0S</scope><scope>M1P</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope></search><sort><creationdate>20110701</creationdate><title>Effects of SLCO1B1 polymorphisms on the pharmacokinetics and pharmacodynamics of repaglinide in healthy Chinese volunteers</title><author>He, Jiake ; Qiu, Zhixia ; Li, Ning ; Yu, Yang ; Lu, Yang ; Han, Deen ; Li, Tingting ; Zhao, Di ; Sun, Wei ; Fang, Fang ; Zheng, Jianheng ; Fan, Hongwei ; Chen, Xijing</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c466t-baae5b89e1c16306807c8b2bbbf3a79632c6d34d0a0c9694b5c20d45e422d38c3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2011</creationdate><topic>Adult</topic><topic>Area Under Curve</topic><topic>Aryl Hydrocarbon Hydroxylases - genetics</topic><topic>Asian Continental Ancestry Group - genetics</topic><topic>Asian people</topic><topic>Biological and medical sciences</topic><topic>Biomedical and Life Sciences</topic><topic>Biomedicine</topic><topic>Carbamates - administration & dosage</topic><topic>Carbamates - pharmacokinetics</topic><topic>Cytochrome P-450 CYP2C8</topic><topic>Cytochrome P-450 CYP3A - genetics</topic><topic>Genotype</topic><topic>Genotype & phenotype</topic><topic>Humans</topic><topic>Hypoglycemic Agents - administration & dosage</topic><topic>Hypoglycemic Agents - pharmacokinetics</topic><topic>Liver-Specific Organic Anion Transporter 1</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Organic Anion Transporters - genetics</topic><topic>Pharmacogenetics</topic><topic>Pharmacology</topic><topic>Pharmacology. Drug treatments</topic><topic>Pharmacology/Toxicology</topic><topic>Piperidines - administration & dosage</topic><topic>Piperidines - pharmacokinetics</topic><topic>Polymerase Chain Reaction</topic><topic>Polymorphism</topic><topic>Polymorphism, Restriction Fragment Length</topic><topic>Polymorphism, Single Nucleotide</topic><topic>Prescription drugs</topic><topic>Prospective Studies</topic><topic>Young Adult</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>He, Jiake</creatorcontrib><creatorcontrib>Qiu, Zhixia</creatorcontrib><creatorcontrib>Li, Ning</creatorcontrib><creatorcontrib>Yu, Yang</creatorcontrib><creatorcontrib>Lu, Yang</creatorcontrib><creatorcontrib>Han, Deen</creatorcontrib><creatorcontrib>Li, Tingting</creatorcontrib><creatorcontrib>Zhao, Di</creatorcontrib><creatorcontrib>Sun, Wei</creatorcontrib><creatorcontrib>Fang, Fang</creatorcontrib><creatorcontrib>Zheng, Jianheng</creatorcontrib><creatorcontrib>Fan, Hongwei</creatorcontrib><creatorcontrib>Chen, Xijing</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Nursing & Allied Health Database</collection><collection>Neurosciences Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><jtitle>European journal of clinical pharmacology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>He, Jiake</au><au>Qiu, Zhixia</au><au>Li, Ning</au><au>Yu, Yang</au><au>Lu, Yang</au><au>Han, Deen</au><au>Li, Tingting</au><au>Zhao, Di</au><au>Sun, Wei</au><au>Fang, Fang</au><au>Zheng, Jianheng</au><au>Fan, Hongwei</au><au>Chen, Xijing</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Effects of SLCO1B1 polymorphisms on the pharmacokinetics and pharmacodynamics of repaglinide in healthy Chinese volunteers</atitle><jtitle>European journal of clinical pharmacology</jtitle><stitle>Eur J Clin Pharmacol</stitle><addtitle>Eur J Clin Pharmacol</addtitle><date>2011-07-01</date><risdate>2011</risdate><volume>67</volume><issue>7</issue><spage>701</spage><epage>707</epage><pages>701-707</pages><issn>0031-6970</issn><eissn>1432-1041</eissn><abstract>Purpose
Repaglinide is commonly used in the treatment of patients with type 2 diabetes mellitus to reduce postprandial hyperglycemia. The objective of this research was to study the effects of
SLCO1B1
polymorphisms on the pharmacokinetics and pharmacodynamics of repaglinide in healthy Chinese volunteers.
Methods
A total of 22 healthy young male participants were recruited from a pool of pharmacogenetically characterized participants genotyped for
SLCO1B1
,
CYP3A4
, and
CYP2C8
SNPs by polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP). Volunteers with
CYP2C8*3
and
CYP3A4*4
alleles were excluded from the clinical study. Then selected volunteers took part in the clinical pharmacokinetic study, receiving 2 mg repaglinide.
Results
Healthy participants with
SLCO1B1*1A/*1B
or
*1A/*1A
genotype and
SLCO1B1 *15/*1A
or
*5/*1A
genotype had significantly higher AUC
0-∞
than participants with
SLCO1B1*1B/*1B
genotype, with the former showing an increase over the latter of 39.81 and 42.09%, respectively (
P
= 0.028, 0.032). The clearance in the former two genotype groups was significantly attenuated (by 27.39 and 28.55%, respectively) compared with individuals with
SLCO1B1*1B/*1B
genotype (
P
= 0.015, 0.019). No significant differences in blood glucose-lowering effect were observed among three genotype groups.
Conclusions
SLCO1B1*1B/*1B
genotype is associated with reduced pharmacokinetic exposure after a single dose oral administration of 2 mg repaglinide, including decreased AUC
0-∞
and increased clearance of repaglinide. Moreover, this polymorphism of
SLCO1B1
has significant influence on the pharmacokinetics of repaglinide, but no effects on its pharmacodynamics.</abstract><cop>Berlin/Heidelberg</cop><pub>Springer-Verlag</pub><pmid>21327909</pmid><doi>10.1007/s00228-011-0994-7</doi><tpages>7</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0031-6970 |
| ispartof | European journal of clinical pharmacology, 2011-07, Vol.67 (7), p.701-707 |
| issn | 0031-6970 1432-1041 |
| language | eng |
| recordid | cdi_proquest_journals_871554183 |
| source | MEDLINE; Springer Nature - Complete Springer Journals |
| subjects | Adult Area Under Curve Aryl Hydrocarbon Hydroxylases - genetics Asian Continental Ancestry Group - genetics Asian people Biological and medical sciences Biomedical and Life Sciences Biomedicine Carbamates - administration & dosage Carbamates - pharmacokinetics Cytochrome P-450 CYP2C8 Cytochrome P-450 CYP3A - genetics Genotype Genotype & phenotype Humans Hypoglycemic Agents - administration & dosage Hypoglycemic Agents - pharmacokinetics Liver-Specific Organic Anion Transporter 1 Male Medical sciences Organic Anion Transporters - genetics Pharmacogenetics Pharmacology Pharmacology. Drug treatments Pharmacology/Toxicology Piperidines - administration & dosage Piperidines - pharmacokinetics Polymerase Chain Reaction Polymorphism Polymorphism, Restriction Fragment Length Polymorphism, Single Nucleotide Prescription drugs Prospective Studies Young Adult |
| title | Effects of SLCO1B1 polymorphisms on the pharmacokinetics and pharmacodynamics of repaglinide in healthy Chinese volunteers |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-02T15%3A44%3A34IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Effects%20of%20SLCO1B1%20polymorphisms%20on%20the%20pharmacokinetics%20and%20pharmacodynamics%20of%20repaglinide%20in%20healthy%20Chinese%20volunteers&rft.jtitle=European%20journal%20of%20clinical%20pharmacology&rft.au=He,%20Jiake&rft.date=2011-07-01&rft.volume=67&rft.issue=7&rft.spage=701&rft.epage=707&rft.pages=701-707&rft.issn=0031-6970&rft.eissn=1432-1041&rft_id=info:doi/10.1007/s00228-011-0994-7&rft_dat=%3Cproquest_cross%3E2373836351%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=871554183&rft_id=info:pmid/21327909&rfr_iscdi=true |